drugset / Trial / NCT05509153
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
Phase 2
Recruiting
160 enrolled
Western Sydney Local Health District
Deakin University · collabMonash University · collabRoyal Perth Hospital · collabThe University of Queensland · collabUniversity of Melbourne · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.
Timeline
- Start
- 2024-06-01
- Primary completion
- 2026-11-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NAC | Unknown | 1 g | Oral |